TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive FY99 Appropriations: Congress Tells NCI To Fund More Research In Prostate Cancer October 30, 1998
TCL Archive In Brief: Hazleton Acquires Prime Labs, Primate Importer; Cullen UCLA Deputy Director July 30, 1976
